Fortress Biotech Inc (FBIO)

$3.90 -0.30 (-7.14%)
Market Cap 130.36M
Revenue (ttm) 57.68M
Net Income (ttm) -46.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -79.75%
Debt to Equity Ratio 0.73
Volume 7,084,600
Avg Vol 680,590
Day's Range N/A - N/A
Shares Out 31.04M
Stochastic %K 33%
Beta 1.42
Analysts Sell
Price Target $10.75

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
IBUYSELLHOLD
IBUYSELLHOLD Jan. 14 at 5:44 AM
$FBIO /many more, this is huge !
0 · Reply
jvbiotek
jvbiotek Jan. 14 at 3:51 AM
$FBIOP $FBIO why is FBIO going down and FBIOP going up? I took position in FBIO.. did I make a mistake?
0 · Reply
braves1983
braves1983 Jan. 14 at 2:29 AM
$FBIO let me guess more selling tomorrow. Cuz why would your want to own this stock?
1 · Reply
makrodimutross
makrodimutross Jan. 14 at 2:27 AM
$FBIOP $FBIO I'm still in the clear here! FBIO won't reach 7 until FBIOP gets to 15 first.
1 · Reply
makrodimutross
makrodimutross Jan. 14 at 2:26 AM
$FBIO $FBIOP Who's still here for Triplex?
1 · Reply
FrodoBag
FrodoBag Jan. 14 at 2:14 AM
$FBIO maybe if some analysts rerate this…
0 · Reply
25_usa
25_usa Jan. 14 at 12:55 AM
$FBIO I'm puzzled why this stock price declined today despite FDA approval. Can someone explain why it also dropped last time when the FDA didn't approve it, but the CRL did?
1 · Reply
holmyown01
holmyown01 Jan. 13 at 11:46 PM
$FBIO prediction for tomorrow?
1 · Reply
FinSUN
FinSUN Jan. 13 at 11:29 PM
$FBIO Textbook hanging man yesterday. Today’s move during regular trading hours provided clean confirmation, almost mechanical. Good technical analysis doesn’t predict the future, but it helps frame probabilities.
0 · Reply
TraderNice
TraderNice Jan. 13 at 11:21 PM
$FBIO This Company Will Be Prrofitable in 2026? FBIO wasn’t profitable before due to insufficient revenue and partial economics ownership. ZYCUBO changes this, but the revenue arrives in stages. 2026 could be their first profitable year, but depends on PRV sale timing, expense control, Journey’s performance, and milestone timing.
0 · Reply
Latest News on FBIO
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Jan 13, 2026, 7:45 AM EST - 20 hours ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

FBIOP

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Dec 10, 2025, 8:30 AM EST - 4 weeks ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

DERM

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 14, 2025, 8:30 AM EST - 2 months ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 10:41 PM EST - 2 months ago

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

FBIOP

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 12, 2025, 4:01 PM EST - 2 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Nov 6, 2025, 7:00 AM EST - 2 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

AXSM

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Nov 5, 2025, 8:30 AM EST - 2 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

DERM

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Oct 24, 2025, 8:30 AM EDT - 2 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

DERM

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Oct 21, 2025, 8:30 AM EDT - 3 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

FBIOP

Journey Medical Corporation to Participate in October 2025 Investor Conferences

Oct 8, 2025, 8:30 AM EDT - 3 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

DERM

Fortress Biotech Investigated by the Portnoy Law Firm

Oct 1, 2025, 3:45 PM EDT - 3 months ago

Fortress Biotech Investigated by the Portnoy Law Firm

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Oct 1, 2025, 8:05 AM EDT - 3 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

FBIOP

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Oct 1, 2025, 8:00 AM EDT - 3 months ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

FBIOP

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Sep 3, 2025, 8:30 AM EDT - 4 months ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

DERM

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 4 months ago

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FBIOP

Journey Medical Corporation to Present at the Emerging Growth Conference

Aug 18, 2025, 8:30 AM EDT - 5 months ago

Journey Medical Corporation to Present at the Emerging Growth Conference

DERM

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 4:05 PM EDT - 5 months ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 5 months ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Aug 7, 2025, 8:30 AM EDT - 5 months ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

DERM

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

DERM

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Jul 14, 2025, 8:30 AM EDT - 6 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

DERM

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Jun 24, 2025, 8:30 AM EDT - 7 months ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

DERM

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Jun 20, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

DERM

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

Jun 9, 2025, 8:30 AM EDT - 7 months ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

DERM

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025, 10:47 AM EDT - 8 months ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIOP

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025, 4:05 PM EDT - 8 months ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 14, 2025, 4:01 PM EDT - 8 months ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

May 13, 2025, 4:15 PM EDT - 8 months ago

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

CKPT

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

May 7, 2025, 4:01 PM EDT - 8 months ago

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

DERM

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 8:00 AM EDT - 8 months ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIOP

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Apr 1, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

DERM

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Mar 31, 2025, 4:05 PM EDT - 10 months ago

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Mar 28, 2025, 8:30 AM EDT - 10 months ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

CKPT

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 7:39 PM EDT - 10 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIOP

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Mar 26, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

DERM

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Mar 24, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

DERM

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Mar 19, 2025, 4:01 PM EDT - 10 months ago

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

DERM

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Mar 17, 2025, 8:55 AM EDT - 10 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIOP

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Mar 12, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

DERM

Sun Pharma to Acquire Checkpoint Therapeutics

Mar 9, 2025, 10:06 PM EDT - 11 months ago

Sun Pharma to Acquire Checkpoint Therapeutics

CKPT

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mar 5, 2025, 4:15 PM EST - 11 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

MBIO

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Mar 5, 2025, 4:01 PM EST - 11 months ago

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

DERM

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Mar 4, 2025, 4:01 PM EST - 11 months ago

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

DERM

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Jan 27, 2025, 8:30 AM EST - 1 year ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

FBIOP

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Jan 23, 2025, 8:30 AM EST - 1 year ago

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

DERM

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Jan 6, 2025, 8:00 AM EST - 1 year ago

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

IBUYSELLHOLD
IBUYSELLHOLD Jan. 14 at 5:44 AM
$FBIO /many more, this is huge !
0 · Reply
jvbiotek
jvbiotek Jan. 14 at 3:51 AM
$FBIOP $FBIO why is FBIO going down and FBIOP going up? I took position in FBIO.. did I make a mistake?
0 · Reply
braves1983
braves1983 Jan. 14 at 2:29 AM
$FBIO let me guess more selling tomorrow. Cuz why would your want to own this stock?
1 · Reply
makrodimutross
makrodimutross Jan. 14 at 2:27 AM
$FBIOP $FBIO I'm still in the clear here! FBIO won't reach 7 until FBIOP gets to 15 first.
1 · Reply
makrodimutross
makrodimutross Jan. 14 at 2:26 AM
$FBIO $FBIOP Who's still here for Triplex?
1 · Reply
FrodoBag
FrodoBag Jan. 14 at 2:14 AM
$FBIO maybe if some analysts rerate this…
0 · Reply
25_usa
25_usa Jan. 14 at 12:55 AM
$FBIO I'm puzzled why this stock price declined today despite FDA approval. Can someone explain why it also dropped last time when the FDA didn't approve it, but the CRL did?
1 · Reply
holmyown01
holmyown01 Jan. 13 at 11:46 PM
$FBIO prediction for tomorrow?
1 · Reply
FinSUN
FinSUN Jan. 13 at 11:29 PM
$FBIO Textbook hanging man yesterday. Today’s move during regular trading hours provided clean confirmation, almost mechanical. Good technical analysis doesn’t predict the future, but it helps frame probabilities.
0 · Reply
TraderNice
TraderNice Jan. 13 at 11:21 PM
$FBIO This Company Will Be Prrofitable in 2026? FBIO wasn’t profitable before due to insufficient revenue and partial economics ownership. ZYCUBO changes this, but the revenue arrives in stages. 2026 could be their first profitable year, but depends on PRV sale timing, expense control, Journey’s performance, and milestone timing.
0 · Reply
IBUYSELLHOLD
IBUYSELLHOLD Jan. 13 at 10:45 PM
$FBIO / they are options killers , thats why I push buying some shares
1 · Reply
wolfman1271
wolfman1271 Jan. 13 at 10:13 PM
$FBIO Well I'm not selling anytime soon, just didn't expect RED
2 · Reply
braves1983
braves1983 Jan. 13 at 10:12 PM
$FBIO I mean so much selling for a company that got fda approval. Why would investors want to buy this stock. Selling it sounds so much better
1 · Reply
TraderNice
TraderNice Jan. 13 at 10:10 PM
$FBIO The company was designed to do this. FBIO’s first-year revenue from ZYCUBO is projected to be between $70 million and $100 million, with the PRV sale being the main contributor. And they achieve this without investing a dime in commercialization.
1 · Reply
ComeOnGuys
ComeOnGuys Jan. 13 at 10:06 PM
$FBIO I guess this is buy the rumor and sell the news price action 🤷🏽‍♂️
0 · Reply
wolfman1271
wolfman1271 Jan. 13 at 10:01 PM
$FBIO I have no idea what's going on after hours either. Just makes no sense.
0 · Reply
TraderNice
TraderNice Jan. 13 at 9:53 PM
$FBIO With this fda approved drug was a big win Securing $12-15 million in Q1 without investing in commercialization is a brilliant and cost-effective strategy. It’s the kind of setup that keeps FBIO afloat during challenging times and gives them the upper hand when the substantial payments come in later this year.
0 · Reply
Zaens
Zaens Jan. 13 at 9:06 PM
$FBIO So weird! Black magic ✨
0 · Reply
ZCOCSTOCK
ZCOCSTOCK Jan. 13 at 8:27 PM
$FBIO out..don’t trust the process on this!
1 · Reply
braves1983
braves1983 Jan. 13 at 8:25 PM
$FBIO thinks typical. Bio stocks don’t head to the moon because fda approval. They head to the moon on a Wednesday just because. There is so much evidence now. All this bio stocks are manipulated
1 · Reply
FuPayMee
FuPayMee Jan. 13 at 7:36 PM
$FBIO
1 · Reply
TheYoungGeologist
TheYoungGeologist Jan. 13 at 7:24 PM
$FBIO Maybe 2 weeks until we catch up to FBIOP?
0 · Reply